智通财经网·2025-12-18 10:49Core Viewpoint - Swiss pharmaceutical giants Novartis (NVS.US) and Roche have expressed support for efforts to lower drug prices in the U.S. and are collaborating with the Trump administration towards this goal [1] Group 1: Company Actions - Novartis is in discussions with the Trump administration to find solutions for reducing drug costs for American citizens and addressing the price disparity between the U.S. and other high-income countries [1] - Roche has stated its support for the goal of lowering drug costs and encourages other countries to reward biopharmaceutical innovation [1] Group 2: Industry Context - The Trump administration has reached out to 17 pharmaceutical companies, urging them to significantly lower drug prices, with Pfizer (PFE.US) and AstraZeneca (AZN.US) being the first to agree to price reductions in exchange for tariff relief [1] - Recent agreements have been made by Eli Lilly (LLY.US) and Novo Nordisk (NVO.US) to substantially reduce the prices of commonly used GLP-1 weight loss drugs for Medicare, Medicaid, and out-of-pocket patients [1]